Define
Context of use, endpoint, population, reference standard, and performance target
Biomarker Discovery
from Omics Data
Develop compact, reproducible molecular signatures for disease classification, prognosis, treatment response, monitoring, pharmacodynamic assessment, and safety research.
Plan Your Biomarker StudyOverview
Build a biomarker signature around a defined context of use
Omics biomarker discovery begins with a specific decision: distinguish disease from health, estimate prognosis, predict treatment response, monitor disease activity, measure pharmacodynamic change, or detect a safety signal. We align cohort structure, molecular measurements, clinical endpoints, statistical analysis, and validation to that intended use.
Our Bioinformatics Services integrate single-omics or multi-omics data with phenotype and clinical variables to identify individual markers or compact multivariable signatures. Candidate panels are evaluated for effect size, stability, incremental value, biological coherence, subgroup consistency, measurement feasibility, and performance in data not used for model development.
ClassificationDisease, subtype, phenotype, or exposure status
Time-to-eventProgression, recurrence, survival, or complication risk
ResponseBenefit, resistance, toxicity, or pharmacodynamic change
MonitoringDisease activity, burden, recovery, or longitudinal trajectory
Human studies are most common; mouse, rat, non-human primate, livestock, plant, microbial, and other supported species can be analyzed where references and annotations are adequate. Specimens may include tissue, biopsy, blood, plasma, serum, urine, CSF, saliva, stool, cells, organoids, extracellular vesicles, and model-system samples.
Development Gates
A staged path from molecular features to a locked biomarker signature
Discover
QC, normalization, association testing, feature screening, and biology
Model
Leakage-safe selection, algorithm tuning, calibration, and stability
Validate
Independent cohort, subgroup analysis, orthogonal measurement, robustness
Translate
Compact panel, locked preprocessing, cut-off strategy, assay handoff
Core Services
Biomarker discovery across molecular layers and study endpoints
Cohort and Endpoint Design
Define discovery, tuning, internal validation, and external validation sets; specify sampling, case definitions, reference standards, censoring, confounders, repeated measures, and acceptance criteria.
Omics QC and Harmonization
Audit raw and processed data, sample identity, missingness, outliers, batch, site, platform drift, composition, annotation, transformation, scaling, and cross-omics sample alignment.
Feature Association Analysis
Model binary, continuous, ordinal, longitudinal, and time-to-event endpoints; report effect sizes, confidence intervals, adjusted significance, and covariate-aware associations.
Multi-Omics Integration
Use early, intermediate, or late integration as appropriate; evaluate concordant pathways, latent factors, network modules, cross-omics interactions, and added value over clinical variables.
Signature and Model Development
Compare sparse regression, tree-based methods, support vector machines, survival models, multiblock methods, and interpretable baselines using nested resampling and in-fold feature selection.
Validation and Assay Translation
Evaluate discrimination, calibration, clinical threshold metrics, subgroup performance, temporal or external transportability, orthogonal assays, panel reduction, and locked analysis specifications.
Six-Stage Workflow
Decision-focused analysis for reproducible biomarker development
| Stage | Key Activities | Decision Output |
|---|---|---|
| 1. Context of use and protocol | Specify biomarker category, target population, endpoint, reference standard, timing, specimen, clinical comparator, minimum useful performance, and planned validation. | Biomarker development charter |
| 2. Cohort and data audit | Assess sample size, event count, class balance, sites, batches, missingness, specimen handling, platform, metadata, repeated measures, confounders, and cohort separability. | Analysis populations and data plan |
| 3. Processing and harmonization | Apply assay-specific QC, normalization, annotation, batch strategy, missing-data handling, cross-omics matching, and preprocessing learned only from training data. | Locked feature matrix and QC report |
| 4. Discovery and model development | Perform association testing, pathway and network interpretation, in-fold feature selection, hyperparameter tuning, signature-size optimization, and comparison with clinical-only baselines. | Candidate markers and provisional models |
| 5. Performance validation | Quantify discrimination, calibration, sensitivity, specificity, predictive values, decision thresholds, survival metrics, uncertainty, subgroup effects, stability, and external performance. | Validated performance profile |
| 6. Translation planning | Prioritize measurable features, reduce the panel, define orthogonal assays, lock preprocessing and cut-offs, assess pre-analytical factors, and plan prospective or analytical validation. | Assay-ready biomarker package |
Deliverables
Traceable outputs from cohort QC to validation planning
✓
Study and Cohort Report
Context of use, cohort definitions, endpoint coding, sample flow, power or precision considerations, event counts, confounders, missingness, and analysis sets.
✓
Omics QC Package
Assay-specific quality metrics, sample identity, outliers, platform and batch structure, normalized data, annotation, cross-omics completeness, and exclusions.
✓
Candidate Biomarker Table
Feature identity, omics layer, effect size, uncertainty, adjusted P value, selection frequency, pathway context, subgroup behavior, and measurement notes.
✓
Locked Signature Specification
Final features, preprocessing, transformations, coefficients or model object, cut-off strategy, software versions, reference annotations, and applicability domain.
✓
Performance and Validation Report
Cross-validation and held-out results, confidence intervals, calibration, ROC/PR or survival metrics, decision thresholds, subgroup analyses, and benchmark comparisons.
✓
Assay Translation Roadmap
Orthogonal measurement options, panel-reduction priorities, pre-analytical variables, analytical validation studies, external cohorts, and prospective validation milestones.
Applications
Biomarker categories aligned to specific development questions
Diagnostic
Identify or classify a disease, molecular subtype, or biological condition.
Prognostic
Estimate the likelihood of progression, recurrence, complications, or survival.
Predictive
Identify individuals more likely to benefit from or resist a specific intervention.
Monitoring
Track disease state, burden, recovery, or longitudinal biological change.
Pharmacodynamic / Response
Measure biological response following an exposure or therapeutic intervention.
Safety
Detect or predict toxicity, organ injury, or adverse biological responses.
Susceptibility / Risk
Estimate the potential to develop a disease or condition before manifestation.
Patient Stratification
Define molecularly coherent groups for trial design or research decisions.
Scientific Evidence
Strong biomarker programs separate discovery from independent validation
A rigorous biomarker program plans the discovery cohort and external test cohort before model development, applies quality control and preprocessing consistently, and evaluates the finalized model on data that were not used to select features or tune parameters.1
High-dimensional omics data frequently contain many more candidate features than samples. Nested cross-validation with feature selection embedded inside the training loop provides a practical framework for tuning models while estimating performance without using information from the held-out folds.2
Our workflow follows these principles while keeping the intended biomarker category and assay path visible from project initiation. This supports biomarker panels that are statistically evaluated, biologically interpretable, and structured for independent and orthogonal validation.
1 Diaz-Uriarte, R. et al. Ten quick tips for biomarker discovery and validation analyses using machine learning. PLoS Computational Biology 2022, 18, e1010357. https://doi.org/10.1371/journal.pcbi.1010357. Open Access, CC BY.
2 Lewis, M.J. et al. nestedcv: an R package for fast implementation of nested cross-validation with embedded feature selection designed for transcriptomics and high-dimensional data. Bioinformatics Advances 2023, 3, vbad048. https://doi.org/10.1093/bioadv/vbad048. Open Access, CC BY 4.0.
3 FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): U.S. Food and Drug Administration; Bethesda (MD): National Institutes of Health; 2016–, updated 2025.
Project Strategy
Performance estimates that remain valid beyond the discovery dataset
Sample size, controls, and uncertainty
Planning considers outcome prevalence, event count, expected effect, model complexity, class imbalance, repeated measures, intended subgroup analyses, and the precision required for performance estimates. Biological replicates, appropriate controls, prespecified exclusions, and independent samples are prioritized over technical replication alone.
Batch, site, and confounding
Collection site, assay batch, storage, specimen handling, demographics, treatment, disease severity, cell composition, and other measured covariates are reviewed before modeling. Harmonization is designed to preserve the outcome signal while avoiding removal of biology that is structurally linked to the study design.
Multiple testing and effect size
Univariate discovery reports effect sizes, confidence intervals, and false-discovery control. Model development evaluates the incremental value of molecular features beyond clinical baselines and tracks signature sparsity, redundancy, and selection stability.
Leakage-safe AI and external validation
Imputation, scaling, batch adjustment, feature filtering, selection, and tuning are learned within training folds. Subjects, sites, families, repeated samples, and time points are grouped as needed. Nested or repeated cross-validation is followed by independent, temporal, or external validation; calibration, applicability domain, and uncertainty accompany model performance.
Computational candidates remain discovery-stage biomarkers until their measurement, reproducibility, biological relevance, and performance are confirmed in appropriate independent samples. We recommend orthogonal assays and, where the intended use requires it, analytical and prospective clinical validation.
To define the appropriate omics layers, cohort structure, endpoint, and validation path for your biomarker project, please Contact Us or submit the Online Inquiry below.
Online Inquiry
Submit your project details below, and our team will respond within 24 hours.
x
Need help getting the data you need?
Talk to our technical team about your project!
I Want To Talk